Treatment of relapsers after combination therapy for chronic hepatitis C

Infectious Disease Clinics of North America
Furqaan Ahmed, Ira M Jacobson

Abstract

Sustained virologic response rates are significantly higher in patients who have relapsed after a previous course of therapy compared with patients who did not respond. A meta-analysis of combination therapy in patients who failed IFN monotherapy reported SVR rates of 52% in relapsers to prior therapy and 16% in nonresponders. Similarly, relapsers after combination standard IFN and RBV therapy have higher SVR rates than combination of therapy nonresponders when treated with pegylated interferon and ribavirin. For this reason, patients who relapse after a previous course of therapy should be considered potential candidates for retreatment. Factors that have been associated with SVR in these patients include genotype non-I, low viral loads, and lesser degrees of fibrosis. The course of treatment in all patients who have relapsed after prior therapy should be reviewed to identify possible reasons for failure to achieve an SVR. In particular, optimal dosing of PEG IFN and RBV and the occurrence and timing of treatment dose reductions during prior therapy should be reviewed. The reasons for dose reduction should be addressed before initiating another course of therapy in an effort to optimize the chance for a SVR. Patients who had d...Continue Reading

References

Sep 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A M Di BisceglieJ H Hoofnagle
Aug 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H C BodenheimerL B Seeff
Sep 26, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G L Davis, J Y Lau
Apr 16, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W C ChowP Marcellin
Sep 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C SarrazinS Zeuzem
Jan 12, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Adrian M Di BisceglieCharles M Rice
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Johnson Y N LauZhi Hong
Jul 20, 2002·Virology·Jason D Graci, Craig E Cameron
Sep 26, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Giorgio SaraccoMario Rizzetto
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Apr 30, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Maria ButiYoav Lurie
Aug 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Gary L DavisJanice Albrecht
Mar 20, 2004·Journal of Hepatology·Johannes T BrouwerUNKNOWN Benelux Study Group On Treatment Of Chronic Hepatitis C
Jun 11, 2004·The Journal of Antimicrobial Chemotherapy·Robert T Sarisky
Sep 4, 2004·Seminars in Liver Disease·Peter Ferenci
Aug 6, 2005·Journal of Hepatology·Edward L KrawittUNKNOWN New York New England Study Team

❮ Previous
Next ❯

Citations

Sep 22, 2006·Enfermedades infecciosas y microbiología clínica·Armando Sánchez-Quijano, Eduardo Lissen-Otero

❮ Previous
Next ❯

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Don C Rockey, D Montgomery Bissell
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Marek RadkowskiTomasz Laskus
© 2021 Meta ULC. All rights reserved